MD, 1982, Beijing College of Chinese Medicine, Beijing, China
MS, 1987, Department of Pathology, Beijing Medical University, Beijing, China
Research Fellow in Pathology, University of Massachusetts Medical Center, Worcester, MA
Residency Training in Anatomic and Clinical Pathology – University of Massachusetts Medical Center, Worcester, MA
Surgical Pathology Fellow, MD Anderson Cancer Center, Houston, TX
I am a surgical pathologist with a specialty in genitourinary pathology (GU) and oncological pathology. My major field of research interest is the development of biomarkers for the diagnosis and prognosis of malignant tumors. I first found P504S/a-methylacyl-CoA racemase (AMACR) to be a good diagnostic marker for prostatic adenocarcinoma in 2001 and then I published a series papers discussing the various diagnostic utilities of P504S/AMACR in prostate cancer and other cancers. Now, P504S/AMACR is being widely used in clinical practice for the diagnosis of prostatic carcinoma. Furthermore, I recently discovered IMP3, an oncofetal protein, as a new prognostic biomarker for renal cell carcinoma and urothelial carcinoma. In addition, IMP3 may have potential diagnostic and prognostic values for other malignant tumors, such as gastrointestinal and gynecological cancers.